Effects of yeast hydrolysate on hepatic lipid metabolism in high-fat-diet-induced obese mice: yeast hydrolysate suppresses body fat accumulation by attenuating fatty acid synthesis.
OBJECTIVE
We observed whether the anti-obesity activity of yeast hydrolysate (YH) was due to the alteration of lipid-regulating enzyme activities.


METHODS
Male ICR mice were divided into four groups: a normal diet group (ND; 4.2% fat), a high-fat diet group (HF; 27.7% fat), an HF group treated orally with 0.5% or 1% YH in the drinking water (HF+YH0.5; 27.7% fat and HF+YH1; 27.7% fat).


RESULTS
After 5 weeks, the YH groups (HF+YH0.5=3.92±0.17 g/100 g BW and HF+YH1=3.76±0.13 g/100 g BW) had significantly lower levels of epididymal fats compared to the HF group (4.91±0.29 g/100 g BW; p<0.05). YH supplementation produced a decrease in serum triglycerides and low-density lipoprotein cholesterol concentrations and body weight gain, and produced a dose-dependent significant increase in serum ghrelin compared with the HF group (p<0.05). Hepatic glucose-6-phosphate dehydrogenase (G6PD) activity was inhibited by YH supplementation compared with the HF group, and mice treated orally with 1% YH exhibited a significant decrease in hepatic malic enzyme (ME) activity compared to obese mice treated with the vehicle (HF=10.44±2.74 nmol/min/mg protein vs. HF+YH1=6.68±2.23 nmol/min/mg protein; p<0.05).


CONCLUSIONS
YH supplementation suppressed body fat accumulation by attenuating fatty acid synthesis through the downregulation of hepatic G6PD and ME activities.
Department of Food and Nutrition, Korea University, Seoul, Korea.
Eun Young
EY
Jung
Yang-Hee
YH
Hong
Jae Hwan
JH
Kim
Yooheon
Y
Park
Song Hwan
SH
Bae
Un Jae
UJ
Chang
Hyung Joo
HJ
Suh
D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology; D008078:Cholesterol, LDL / Q000097:blood; D059305:Diet, High-Fat; D015536:Down-Regulation; D054439:Ghrelin / Q000097:blood; D005954:Glucosephosphate Dehydrogenase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D020738:Leptin / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects*; D050155:Lipogenesis / Q000187:drug effects*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008291:Malate Dehydrogenase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011492:Protein Hydrolysates / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects; D015003:Yeasts / Q000201:enzymology*
D019440:Anti-Obesity Agents; D008078:Cholesterol, LDL; D054439:Ghrelin; D020738:Leptin; D011492:Protein Hydrolysates; D014280:Triglycerides; D008291:Malate Dehydrogenase; D005954:Glucosephosphate Dehydrogenase